A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer.

CONCLUSION: This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone.
PMID: 31796519 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 2, 2019 Category: Cancer & Oncology Authors: Rodriguez CP, Wu Q, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, Lee SM, Santana-Davila R, Goulart B, Baik CS, Chow LQM, Eaton K, Martins R Tags: Clin Cancer Res Source Type: research